Immune response to GeneVac-BⓇ (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso
Nina Genéviève Mathuola Ouattara, Armel Moumouni Sanou, Delphine Napon-Zongo, Abou Coulibaly, Sylviane Korogho, Abdoulaye Dera, Achille S Nikièma, Eric Kyelem, Nawatou Gansoré, Abdoul Kader Ilboudo, Jeoffray Diendéré, Gautier Henri Ouédraogo · 2024
Read Immune response to GeneVac-BⓇ (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso by Nina Genéviève Mathuola Ouattara, Armel Moumouni Sanou, Delphine Napon-Zongo, Abou Coulibaly, Sylviane Korogho, Abdoulaye Dera, Achille S Nikièma, Eric Kyelem, Nawatou Gansoré, Abdoul Kader Ilboudo, Jeoffray Diendéré, Gautier Henri Ouédraogo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11618024.txt.
Description
Highlights•GeneVac-B® showed an excellent immune response.•Its low cost makes it a good tool to prevent hepatitis B infection.•Post-vaccination evaluation should be considered in persons with comorbidities.Keywords: Hepatitis B, GeneVac-BⓇ, Immune response, Nonresponse factors, Burkina Faso Introduction Hepatitis B virus (HBV) infection remains a significant public health problem worldwide despite the availability of prevention methods and effective antivirals [1].
Catalog record
| CREATOR | Nina Genéviève Mathuola Ouattara, Armel Moumouni Sanou, Delphine Napon-Zongo, Abou Coulibaly, Sylviane Korogho, Abdoulaye Dera, Achille S Nikièma, Eric Kyelem, Nawatou Gansoré, Abdoul Kader Ilboudo, Jeoffray Diendéré, Gautier Henri Ouédraogo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |